Novo Nordisk has announced plans to invest in the expansion of existing facilities in Bagsværd, Denmark. The plans also include the construction of a new plant located in extension of
Nordic Life Science
NOT A SUBSCRIBER? SIGN UP TODAY AND GET THE FULL LIFE SCIENCE PICTURE
ONLY 13 €/MONTH
NLS News
Copenhagen Science City has one of Europe’s highest concentrations of education and research in the fields of medicine, health and natural sciences. The development of Copenhagen Science City started during
The new project, PD-BT2238, combines a selective alpha-synuclein oligomer targeting antibody with BioArctic’s Brain Transporter technology, to increase exposure of the antibody in the brain, with the aim of increasing
The Board of LINK Medical has announced the appointment of Sissel Lønning Andresen as the company’s new CEO. Ola Gudmundsen will remain in the company in a strategic role where
Abera Bioscience has found the right recipe for giving its innovative and versatile vaccine platform the best possible conditions to succeed. Uppsala-based Abera Bioscience was founded ten years ago, as
HUS Helsinki University Hospital, University of Helsinki, Janssen Finland and Janssen EMEA have agreed on extensive international collaboration. Its aim is to promote the development of value-based healthcare and to
AstraZeneca and Daiichi Sankyo’s Enhertu has been recommended for approval in the European Union as monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma
Evaxion Biotech has announced that it intends to further increase its focus on its lead oncology assets EVX-01 and EVX-02/03 to bring them to clinical proof of concept followed by
Advertisement
The two companies announce that the European Commission has granted a marketing authorization for Ximluci (ranibizumab), a biosimilar candidate referencing Lucentis. This follows the positive opinion issued by the European
Devyser announces its decision to establish a CLIA lab in Atlanta, Georgia, USA. By operating a CLIA lab, Devyser obtains complete control of the selling process, including reimbursement management, ensuring
Nordic Nanovector and all shareholders of APIM Therapeutics have entered into a definitive merger agreement to combine the companies in an all-stock transaction. Subject to completion of the agreement, Nordic
The U.S. Food and Drug Administration has granted RMC-035 the designation for reducing the risk of an irreversible loss of kidney function, initiation of kidney replacement therapy or death following
Salipro Biotech has entered into a research collaboration and license agreement with Sanofi on the discovery of therapeutic biologics against a challenging drug target. The collaboration brings together Salipro Biotech’s
The company has opened an office in Boston to support its increasing US clinical development, partnering and fund-raising activities. The new office is at the CIC in Boston, Massachusetts which
The Nobel Prize 2022
The Royal Swedish Academy of Sciences has decided to award the Nobel Prize in Chemistry to Carolyn R. Bertozzi, Stanford University, USA, Morten Meldal, University of Copenhagen, Denmark, and K.
The Nobel Prize in Chemistry 2022 is about making difficult processes easier, describes the Royal Swedish Academy of Sciences. “This year’s Prize in Chemistry deals with not overcomplicating matters, instead
Svante Pääbo receives the Prize for his discoveries concerning the genomes of extinct hominins and human evolution. Svante Pääbo was born 1955 in Stockholm, Sweden. He defended his PhD thesis
The COVID-19 pandemic
Nykode Therapeutics has announced clinical results from the open label, dose escalation trial of its T cell focused pan-SARS-CoV-2 vaccine candidate (VB10.2210) in healthy individuals who were previously vaccinated with
Drug and device development
Nordic Nanovector has provided an update on PARADIGME, its Phase 2b trial of Betalutin in 3rd-line relapsed and anti-CD20 refractory follicular lymphoma. Following a comprehensive review and independent data evaluation
Evaxion Biotech has announced clinical data from the first-in-human study of its DNA-based cancer immunotherapy, EVX-02. In the clinical study, EVX-02 is given in combination with a checkpoint inhibitor and
EpiEndo Pharmaceuticals has received regulatory approval to commence a Phase 2a clinical trial with lead molecule EP395 in COPD (Chronic Obstructive Pulmonary Disease) patients. EP395 is an orally available macrolide
Affibody’s licensee Rallybio Corporation has announced positive topline results from a Phase 1 single ascending dose (SAD) study in healthy participants of RLYB116. In the ongoing Phase 1 study, all
Cantargia has reported new data providing further insights to the mechanisms underlying the antitumor activity of the IL1RAP-binding antibody nadunolimab (CAN04). In a model of the pancreatic cancer (PDAC) microenvironment,
Profile
One of Nobel Laureate David Julius’ greatest joys is when people in his lab show him exciting data and make their own discoveries, and as a scientist and educator his
In a new job
Anki Malmborg Hager has extensive experience in the life sciences, including as a business developer and CEO of the Lund companies Cantargia, Diaprost, Senzagen and PainDrainer. “We’re thrilled to have
Careers
Tanja Dowe, Head of Debiopharm Innovation Fund, gives us her insights from the hard but exciting work of building a life science business and what it takes to make it
Read the latest issue of our magazine!
No 04 2022 // Welcome to our 15th Nobel Prize issue! We have decided to return to an old tradition and publish this issue in November, just in time for the glittering Nobel festivities, when the whole world’s attention is drawn to the Nordic region. This year we also have two Nordic (!) Laureates within the field of life sciences, Swedish Svante Pääbo and Danish Morten Meldal.
In addition, we have spoken to Business Region Göteborg’s investment advisor Iris Öhrn, we have found out what’s behind Nordic Biomarker’s recent success and we take a closer look on the critical role of Nordic CDMOs. This issue also includes a commentary about recent trends in healthcare, a perspective about Real-World Data, and interviews with the new CEOs of Industrifonden and SwedenBIO.
This, and much more, in our latest issue – out now!
Venture Capital
Nordic Life Science asked Fredrik Dahl, co-founder at Colibri Ventures, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges Nordic life science
Nordic Life Science asked Claus Andersson, General Manager at Sunstone Life Science Venture, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges
Nordic Life Science asked Inka Mero, Founder and Managing Partner at Voima Ventures, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges
“Start by asking what the problem is that you are trying to solve and develop the technology, team, and plan to solve that problem – not what you can do with the technology.” – Fredrik Dahl, Colibri Ventures
Upcoming events
This event will be delivered in-person in Strasbourg November 29-30, and online December 7-8. With the highest attending rate of academics, TTOs and research institutions, BioFIT is the place where academia-industry
This event is back in-person on January 9-11, but will also be arranged as a virtual event a few days later. The program will feature insights from top investors and
This 41st annual healthcare meeting will take place at Westin St. Francis Hotel in San Francisco, CA, USA. This conference brings together industry leaders, emerging companies, innovative technology creators and
Cancer Crosslinks promotes interactions between researchers and clinicians, and encourages translational and clinical research. This event has become a leading forum, gathering oncologists, hematologists, translational researchers, healthcare providers, regulatory experts, and
The latest research news from the Nordic region
Science Article
Olink Holding has announced the 2022 winner of the young researchers’ award, Novelties in Biomarkers, Maria Martin-Grau at the University of Valencia, Spain. Novelties in Biomarkers is an annual award
The European Patent Office (EPO) has honoured Hungarian-American researcher Katalin Karikó with the European Inventor Award 2022 in the category “Lifetime achievement”, for her seminal work in developing modified messenger
Dr Martin Oeggerli at Micronaut GmBH, Basel, Switzerland, is this year’s winner of the Lennart Nilsson Award. Martin Oeggerli holds a PhD in medical molecular biology. Since 2005, he works
Emma Lundberg, Professor in Cell Biology Proteomics at KTH, Associate Professor of Bioengineering and Pathology at Stanford University, and Head of the Subcellular Section of the Human Protein Atlas, has
On International Women’s Day we like to highlight some of the many inspiring women in life science that we have had the opportunity to meet and interview. Within life science
Jens Bukh has contributed to giving thousands of people a better and longer life through his research within hepatitis C. Jens Bukh heads the Copenhagen Hepatitis C Program at the
Nordic Life Science
The latest clinical trials
Evaxion Biotech has announced clinical data from the first-in-human study of its DNA-based cancer immunotherapy, EVX-02. In the clinical study, EVX-02 is given in combination with a checkpoint inhibitor and
EpiEndo Pharmaceuticals has received regulatory approval to commence a Phase 2a clinical trial with lead molecule EP395 in COPD (Chronic Obstructive Pulmonary Disease) patients. EP395 is an orally available macrolide
Affibody’s licensee Rallybio Corporation has announced positive topline results from a Phase 1 single ascending dose (SAD) study in healthy participants of RLYB116. In the ongoing Phase 1 study, all
Cantargia has reported new data providing further insights to the mechanisms underlying the antitumor activity of the IL1RAP-binding antibody nadunolimab (CAN04). In a model of the pancreatic cancer (PDAC) microenvironment,
Gesynta Pharma has announced the decision to advance the development of its clinical-stage drug candidate GS-248 in endometriosis. This strategically important decision follows a recent preclinical proof-of-concept study with GS-248
Ultimovacs has announced that the first patient has been randomized in the LUNGVAC study. The study in non-small cell lung cancer (NSCLC) is the fifth Phase II clinical trial in
BerGenBio has announced the initiation of a trial evaluating bemcentinib in combination with the current standard of care, checkpoint inhibitor pembrolizumab and doublet chemotherapy, for the treatment of 1st line
Nykode Therapeutics has announced clinical results from the open label, dose escalation trial of its T cell focused pan-SARS-CoV-2 vaccine candidate (VB10.2210) in healthy individuals who were previously vaccinated with
TILT Biotherapeutics has announced that the first US patient has been dosed in its ovarian cancer trial, using its oncolytic adenovirus, TILT-123. This open-label, phase I, dose-escalation, multicenter, and multinational,
Sign up to our newsletter
[mc4wp_form id="id=``11984``"]
NOT A SUBSCRIBER? SIGN UP TODAY AND GET THE FULL LIFE SCIENCE PICTURE
ONLY 13 €/MONTH
Advertisement